CRANFORD, N.J., May 23, 2012 /PRNewswire/ -- Akrimax Pharmaceuticals announced the launch of Suprenza (phentermine HCl) orally disintegrating tablets (ODT) as a short-term adjunct in the management of exogeneous obesity. Obesity is a major concern in the United States and has been associated with increases in high blood pressure, diabetes, and other diseases. Suprenza is a sympathomimetic amine anorectic indicated for patients with an initial body mass index (BMI) of greater than or equal to 30kg/m squared or greater than or equal to 27kg/m squared in the presence of other risk factors (eg, controlled hypertension, diabetes, and hyperlipidemia).
Suprenza ODT is available from Akrimax in 15mg and 30mg dosage strengths. Dr. Keith Rotenberg (Corporate Vice President and Chief Scientific Officer) acknowledges findings from the US Centers for Disease Control and Prevention show that current statistics estimate over one third of the US population is overweight and another third of the population is obese. Dr. Rotenberg states that, “Suprenza provides physicians with a novel treatment alternative in the battle against obesity. Suprenza’s unique formulation offers the patient the convenience of taking Suprenza with or without water and without regard to when the last meal was ingested.” To assist patients with their weight loss, Akrimax has also created the Suprenza LEAN Program (Lifestyle, Exercise and Nutrition), which can be found at www.suprenza.com, along with further information on Suprenza.
Akrimax Pharmaceuticals is a privately-held, innovative specialty pharmaceutical company that acquires, develops and markets advanced ethical prescription medications. In addition to Suprenza ODT, the current company portfolio of products includes Tirosint ® (levothyroxine sodium), Primlev (oxycodone/acetaminophen), NitroMist® (nitroglycerin lingual aerosol), and Inderal® LA. More information on Akrimax and its products can be obtained at www.akrimax.com.
SOURCE Akrimax Pharmaceuticals
